Antigen binding molecules for small cell lung cancer
Small cell lung cancer specific chimeric antigen receptor comprising: an antigen-binding domain capable of specifically binding an antigen selected from Tables 1A, 1B, 2A, 2B and 4 and/or that specifically binds to or interacts GAD65, PTPRU, TFRC and GABA-b. A method for treating a subject suffering from SCLC comprising, introducing into the subject a therapeutically effective amount of a T lymphocyte comprising a chimeric antigen receptor. An antigen binding molecule, comprising: an antigen-binding domain capable of specifically binding an antigen selected from Tables 1A, 1B, 2A, 2B and 4 and/or that specifically binds to or interacts GAD65, PTPRU, TFRC and GABA-b. A method of detecting an SCLC tumor in a subject.
1. A method of treating small cell lung cancer (SCLC) in a subject that has been diagnosed with limited stage SCLC, the method comprising administering to the subject a chemotherapy regimen or an immunotherapy regimen to the subject, wherein the subject has been diagnosed with limited stage SCLC by:
(a) contacting a biological sample obtained from the subject with an array consisting essentially of antigens capable of specifically binding, respectively, to four autoantibodies, wherein the four autoantibodies are anti-GAD65 antibodies, anti-PTPRU antibodies, anti-TFRC antibodies, and anti-GABA-b antibodies;
(b) detecting an amount of the four autoantibodies present in the biological sample when the autoantibodies bind to the antigens in the array; and
(c) diagnosing limited stage SCLC in the subject when the amount of the four autoantibodies in the biological sample exceeds, respectively, a control amount.
2. The method of claim 1 , wherein the control amount is an amount determined in a population of healthy individuals.
3. The method of claim 1 , wherein the biological sample is a plasma sample.
4. The method of claim 1 , wherein the immunotherapy regimen includes administration of a population of human T cells engineered to express a chimeric antigen receptor that binds an antigen selected from the group consisting of GAD65, PTPRU, TFRC, and GABA-b.
5. The method of claim 1 , wherein the subject is a human.
6. The method of claim 5 , wherein the subject is a smoker.
7. The method of claim 5 , wherein the subject is a former smoker.
8. The method of claim 1 , further comprising obtaining the biological sample from the subject.
9. A method of treating small cell lung cancer (SCLC) in a subject that has been diagnosed with limited stage SCLC, the method comprising administering to the subject a chemotherapy regimen or an immunotherapy regimen to the subject, wherein the subject has been diagnosed with limited stage SCLC by:
(a) contacting a biological sample obtained from the subject with an array consisting essentially of antibodies capable of specifically binding, respectively, to four antigen-autoantibody complexes, wherein the four antigen-autoantibody complexes are a GAD65-autoantibody complex, a PTPRU-autoantibody complex, a TFRC-autoantibody complex, and a GABA-b-autoantibody complex;
(b) detecting an amount of the four complexes present in the biological sample when the complexes bind to the antibodies in the array; and
(c) diagnosing SCLC in the subject when the amount of the four complexes in the biological sample exceeds, respectively, a control amount.
10. The method of claim 9 , wherein the control amount is an amount determined in a population of healthy individuals.
11. The method of claim 9 , wherein the biological sample is a plasma sample.
12. The method of claim 9 , wherein the immunotherapy regimen includes administration of a population of human T cells engineered to express a chimeric antigen receptor that binds an antigen selected from the group consisting of GAD65, PTPRU, TFRC, and GABA-b.
13. The method of claim 12 , wherein the subject is a human.
14. The method of claim 13 , wherein the subject is a smoker.
15. The method of claim 13 , wherein the subject is a former smoker.
16. The method of claim 9 , further comprising obtaining the biological sample from the subject.
17. A biomarker detection array for limited stage small cell lung cancer (SCLC) consisting essentially of:
antibodies capable of specifically binding, respectively, to four antigen-autoantibody complexes, wherein the four antigen-autoantibody complexes are a GAD65-autoantibody complex, a PTPRU-autoantibody complex, a TFRC-autoantibody complex, and a GABA-b-autoantibody complex.
18. The array of claim 17 , consisting of four antibodies, wherein the four antibodies bind, respectively, to an epitope from an antigen selected from a GAD65-autoantibody complex, a PTPRU-autoantibody complex, a TFRC-autoantibody complex, and a GABA-b-autoantibody complex.